Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

Subgroup analyses of a randomized global phase II study of axitinib showed objective response rate of 66% and median progression‐free survival of 27.6 months in treatment‐naïve Japanese patients with metastatic renal cell carcinoma (RCC). This analysis evaluated overall survival (OS) and safety in 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Oya, Mototsugu, Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480076/
https://www.ncbi.nlm.nih.gov/pubmed/28267243
http://dx.doi.org/10.1111/cas.13232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480076/
https://www.ncbi.nlm.nih.gov/pubmed/28267243
http://dx.doi.org/10.1111/cas.13232

Ejemplares similares